An evaluation of the efficacy of Repeton on proliferation of Peripheral Neuropathy.
An in-house study by The Gordon's Herbal Research Center (GHRC)

Experiments were performed in our research center to study the effects of Repeton on the containment of Peripheral Neuropathy. Repeton was administered orally through pill form to the sample group of patients.

Twenty data points for each patient were collected and evaluated using statistical methods to compare progress.

Data indicates that Repeton is efficacious in the treatment of Peripheral Neuropathy. These preliminary laboratory studies and histological evaluation of patients who received Repeton indicate that the compound should be tested on larger samples in a higher level study to confirm observations further..

Another controlled study to test the efficacy of Repeton for Peripheral Neuropathy.
Repeton has been proposed as a herbal remedy for Peripheral Neuropathy.

In a preliminary controlled study, Repeton has been administered orally in pill form in set group of patients.

Results were obtained for 200 patients . All had previous treatments of various natures.

The results from these treatments consisted of symptomatic relief.

None of the patients were receiving any oral or topical medications at the time of the Repeton experiment.

Administration of Repeton was continued until two weeks in addition to the time of complete disappearance of symptoms.

The trial periods ranged from four to twelve weeks.

Follow-ups after experiment ranged from seven months to three years and showed results clinical recurrences.

Here is a summary of the clinical trail conducted in compliance
with the protocol, cGCP requirements:

The extensive report includes over 300 pages and is 18 megabytes in size. The trials were labelled as successful.
The study concludes that 72 percent of patients experienced reduction of 1 or more on the Physician’s Global Assessment (PGA).
53 percent of users saw a Physician’s Global Assessment (PGA) reduction of 2 or more.
17 percent saw a reduction of 3 or more.
67 percent of patients who started with a PGA of 4 (the most severe in the patient population) experienced reduction of 2 or more.
89 percent of patients who started with a PGA of 4 (the most severe) experienced reduction of 1 or more on a scale of 5 in the PGA.
91 percent of the patents started the study with a condition classified as “deteriorating.”
100 percent of the patients tested experienced no side effects while using Repeton.
Based on this data it is believed that if the trial period was longer, the results would have been even better.
The clinical trials on Repeton were conducted under necessary requirements of clinical testing procedures.